Published in Clin Exp Metastasis on November 16, 2007
Concomitant oral tyrosine kinase inhibitors and bisphosphonates in advanced renal cell carcinoma with bone metastases. Br J Cancer (2012) 1.35
Therapeutic targets for bone metastases in breast cancer. Breast Cancer Res (2011) 1.16
Breast cancer metastasis to the bone: mechanisms of bone loss. Breast Cancer Res (2010) 1.15
Osteopontin genetic variants are associated with overall survival in advanced non-small-cell lung cancer patients and bone metastasis. J Exp Clin Cancer Res (2013) 1.07
Lung tumor-associated osteoblast-derived bone morphogenetic protein-2 increased epithelial-to-mesenchymal transition of cancer by Runx2/Snail signaling pathway. J Biol Chem (2011) 1.00
Metastatic tumors to the jaws and mouth. Head Neck Pathol (2014) 1.00
Molecular mechanisms of bone metastasis and associated muscle weakness. Clin Cancer Res (2014) 0.97
Cancer-associated bone disease. Osteoporos Int (2013) 0.94
New advances on critical implications of tumor- and metastasis-initiating cells in cancer progression, treatment resistance and disease recurrence. Histol Histopathol (2010) 0.93
Establishment of a biomarker model for predicting bone metastasis in resected stage III non-small cell lung cancer. J Exp Clin Cancer Res (2012) 0.90
Src signaling pathways in prostate cancer. Cancer Metastasis Rev (2014) 0.86
Finite element analysis and CT-based structural rigidity analysis to assess failure load in bones with simulated lytic defects. Bone (2013) 0.85
RANK-mediated signaling network and cancer metastasis. Cancer Metastasis Rev (2014) 0.85
Cytosine arabinoside induces ectoderm and inhibits mesoderm expression in human embryonic stem cells during multilineage differentiation. Br J Pharmacol (2011) 0.84
Tumour-derived miRNAs and bone metastasis. Bonekey Rep (2015) 0.83
Effects of intravenous zoledronic acid and oral ibandronate on early changes in markers of bone turnover in patients with bone metastases from non-small cell lung cancer. Int J Clin Oncol (2011) 0.83
Nitrogen-containing bisphosphonates inhibit RANKL- and M-CSF-induced osteoclast formation through the inhibition of ERK1/2 and Akt activation. J Biomed Sci (2014) 0.83
Breast cancer at bone metastatic sites: recent discoveries and treatment targets. J Cell Commun Signal (2011) 0.81
Tetrahydrofurofuran-type lignans inhibit breast cancer-mediated bone destruction by blocking the vicious cycle between cancer cells, osteoblasts and osteoclasts. Invest New Drugs (2013) 0.80
Combination of the c-Met inhibitor tivantinib and zoledronic acid prevents tumor bone engraftment and inhibits progression of established bone metastases in a breast xenograft model. PLoS One (2013) 0.80
RANK/OPG ratio of expression in primary clear-cell renal cell carcinoma is associated with bone metastasis and prognosis in patients treated with anti-VEGFR-TKIs. Br J Cancer (2015) 0.79
TMPRSS2-ERG fusion promotes prostate cancer metastases in bone. Oncotarget (2016) 0.78
The effect of relaxin on the musculoskeletal system. Scand J Med Sci Sports (2013) 0.77
Semaphorin 4D Promotes Skeletal Metastasis in Breast Cancer. PLoS One (2016) 0.77
Paracrine-mediated osteoclastogenesis by the osteosarcoma MG63 cell line: is RANKL/RANK signalling really important? Clin Exp Metastasis (2011) 0.76
Bone-Targeted Agents for the Management of Breast Cancer Patients with Bone Metastases. J Clin Med (2013) 0.76
Bone Targeted Therapies for Bone Metastasis in Breast Cancer. J Clin Med (2013) 0.76
Alteration of osteoblast arrangement via direct attack by cancer cells: New insights into bone metastasis. Sci Rep (2017) 0.75
Thoracic Temporal Subtraction Three Dimensional Computed Tomography (3D-CT): Screening for Vertebral Metastases of Primary Lung Cancers. PLoS One (2017) 0.75
Basigin-2 upregulated by receptor activator of NF-κB ligand enhances lung cancer-induced osteolytic lesions. Cancer Cell Int (2016) 0.75
Outcomes of metastatic spinal cord compression secondary to primary hepatocellular carcinoma with multidisciplinary treatments. Oncotarget (2017) 0.75
In vitro comparison of new bisphosphonic acids and zoledronate effects on human gingival fibroblasts viability, inflammation and matrix turnover. Clin Oral Investig (2015) 0.75
Clustering of patients with intrahepatic cholangiocarcinoma based on serum periostin may be predictive of prognosis. Oncol Lett (2017) 0.75
Development and characterization of murine models of medulloblastoma extraneural growth in bone. Clin Exp Metastasis (2013) 0.75
Involvement of chemokine receptors in breast cancer metastasis. Nature (2001) 26.07
The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited. Nat Rev Cancer (2003) 22.78
Cancer metastasis: building a framework. Cell (2006) 19.67
Osteoblastic cells regulate the haematopoietic stem cell niche. Nature (2003) 19.60
Targeted disruption of the c-src proto-oncogene leads to osteopetrosis in mice. Cell (1991) 14.89
The distribution of secondary growths in cancer of the breast. 1889. Cancer Metastasis Rev (1989) 13.15
Tumor metastasis: mechanistic insights and clinical challenges. Nat Med (2006) 11.06
Mechanisms of bone metastasis. N Engl J Med (2004) 10.40
Cancer stem cells: an old idea--a paradigm shift. Cancer Res (2006) 9.76
Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res (2006) 7.83
Distinct organ-specific metastatic potential of individual breast cancer cells and primary tumors. J Clin Invest (2005) 6.10
Osteoimmunology: shared mechanisms and crosstalk between the immune and bone systems. Nat Rev Immunol (2007) 5.86
Regulation of cancer cell migration and bone metastasis by RANKL. Nature (2006) 5.27
Pathogenesis of osteoporosis: concepts, conflicts, and prospects. J Clin Invest (2005) 5.19
Inflammation, a key event in cancer development. Mol Cancer Res (2006) 5.03
Skeletal remodeling in health and disease. Nat Med (2007) 4.31
The stem cell niches in bone. J Clin Invest (2006) 4.11
Metastasis: recent discoveries and novel treatment strategies. Lancet (2007) 3.93
Dormancy of mammary carcinoma after mastectomy. J Natl Cancer Inst (1999) 3.78
Normal stem cells and cancer stem cells: the niche matters. Cancer Res (2006) 3.60
Mammary stem cells, self-renewal pathways, and carcinogenesis. Breast Cancer Res (2005) 3.05
Basic mechanisms responsible for osteolytic and osteoblastic bone metastases. Clin Cancer Res (2006) 2.69
Mesenchymal to epithelial transition in development and disease. Cells Tissues Organs (2007) 2.59
Temporal progression of metastasis in lung: cell survival, dormancy, and location dependence of metastatic inefficiency. Cancer Res (2000) 2.58
Skeletal localization and neutralization of the SDF-1(CXCL12)/CXCR4 axis blocks prostate cancer metastasis and growth in osseous sites in vivo. J Bone Miner Res (2004) 2.36
Anticancer therapies combining antiangiogenic and tumor cell cytotoxic effects reduce the tumor stem-like cell fraction in glioma xenograft tumors. Cancer Res (2007) 2.35
Metastatic breast cancer: clinical course, prognosis and therapy related to the first site of metastasis. Breast Cancer Res Treat (2000) 2.33
Inhibition of breast cancer metastasis by selective synthetic polypeptide against CXCR4. Cancer Res (2004) 2.31
Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer. J Clin Oncol (1996) 2.27
Randomized active-controlled phase II study of denosumab efficacy and safety in patients with breast cancer-related bone metastases. J Clin Oncol (2007) 2.24
Clinical course and prognostic factors following bone recurrence from breast cancer. Br J Cancer (1998) 2.20
Bone remodeling. Ann N Y Acad Sci (2006) 2.18
The Runx2 osteogenic transcription factor regulates matrix metalloproteinase 9 in bone metastatic cancer cells and controls cell invasion. Mol Cell Biol (2005) 2.18
A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer. Clin Cancer Res (2006) 1.99
Impaired intranuclear trafficking of Runx2 (AML3/CBFA1) transcription factors in breast cancer cells inhibits osteolysis in vivo. Proc Natl Acad Sci U S A (2005) 1.83
Are nonresorbing osteoclasts sources of bone anabolic activity? J Bone Miner Res (2007) 1.82
Signal transduction of inflammatory cytokines and tumor development. Cancer Sci (2006) 1.78
Osteoblast-related transcription factors Runx2 (Cbfa1/AML3) and MSX2 mediate the expression of bone sialoprotein in human metastatic breast cancer cells. Cancer Res (2003) 1.57
Tumor alphavbeta3 integrin is a therapeutic target for breast cancer bone metastases. Cancer Res (2007) 1.55
Role of endothelin-1 in osteoblastic bone metastases. Cancer (2003) 1.54
C-SRC tyrosine kinase activity is associated with tumor colonization in bone and lung in an animal model of human breast cancer metastasis. Cancer Res (2003) 1.52
Ki26894, a novel transforming growth factor-beta type I receptor kinase inhibitor, inhibits in vitro invasion and in vivo bone metastasis of a human breast cancer cell line. Cancer Sci (2007) 1.45
Osteoprotegerin inhibits osteolysis and decreases skeletal tumor burden in syngeneic and nude mouse models of experimental bone metastasis. Cancer Res (2001) 1.44
The osteoclast-associated protease cathepsin K is expressed in human breast carcinoma. Cancer Res (1997) 1.43
Human osteocalcin and bone sialoprotein mediating osteomimicry of prostate cancer cells: role of cAMP-dependent protein kinase A signaling pathway. Cancer Res (2005) 1.41
Stromal-epithelial interaction in prostate cancer progression. Clin Genitourin Cancer (2006) 1.33
Solitary cancer cells as a possible source of tumour dormancy? Semin Cancer Biol (2001) 1.30
The multiple roles of osteoclasts in host defense: bone remodeling and hematopoietic stem cell mobilization. Annu Rev Immunol (2007) 1.27
The role of tumor microenvironment in prostate cancer bone metastasis. J Cell Biochem (2007) 1.26
Inhibition of protein kinase c-Src reduces the incidence of breast cancer metastases and increases survival in mice: implications for therapy. J Pharmacol Exp Ther (2006) 1.26
Type I collagen receptor (alpha 2 beta 1) signaling promotes the growth of human prostate cancer cells within the bone. Cancer Res (2006) 1.24
Mechanisms of osteopontin and CD44 as metastatic principles in prostate cancer cells. Mol Cancer (2007) 1.24
The incidence of late recurrence (greater than 10 years); an analysis of 536 consecutive cases of cutaneous melanoma. Br J Plast Surg (1989) 1.21
Targeting bone metastasis in prostate cancer with endothelin receptor antagonists. Clin Cancer Res (2006) 1.19
Vascular endothelial growth factor contributes to prostate cancer-mediated osteoblastic activity. Cancer Res (2005) 1.17
Therapy insight: the risks and benefits of bisphosphonates for the treatment of tumor-induced bone disease. Nat Clin Pract Oncol (2007) 1.17
A cathepsin K inhibitor reduces breast cancer induced osteolysis and skeletal tumor burden. Cancer Res (2007) 1.15
Back to the future: COX-2 inhibitors for chemoprevention and cancer therapy. Mini Rev Med Chem (2007) 1.12
Stimulation of cyclooxygenase-2 expression by bone-derived transforming growth factor-beta enhances bone metastases in breast cancer. Cancer Res (2006) 1.12
Lack of noggin expression by cancer cells is a determinant of the osteoblast response in bone metastases. Am J Pathol (2007) 1.10
The Src signaling pathway: a potential target in melanoma and other malignancies. Expert Opin Ther Targets (2007) 1.10
Bone metastases from breast carcinoma: histopathological - radiological correlations and prognostic features. Br J Cancer (2003) 1.08
Inhibition of protein kinase c-Src as a therapeutic approach for cancer and bone metastases. Anticancer Agents Med Chem (2008) 1.08
Human breast cancer: survival from first metastasis. Breast Cancer Study Group. Breast Cancer Res Treat (1992) 1.07
Bone metastasis in prostate cancer: molecular and cellular mechanisms (Review). Int J Mol Med (2007) 1.06
Skeletal development, bone remodeling, and hematopoiesis. Immunol Rev (2005) 1.05
Breast cancer-derived factors facilitate osteolytic bone metastasis. Bull Cancer (2006) 1.02
Downregulation of osteopontin and bone sialoprotein II is related to reduced colony formation and metastasis formation of MDA-MB-231 human breast cancer cells. Cancer Gene Ther (2004) 1.00
Angiogenesis in cancer: molecular mechanisms, clinical impact. Langenbecks Arch Surg (2007) 0.98
Tumor metastasis to bone. Arthritis Res Ther (2007) 0.98
Evolution of cancer stem cells. Semin Cancer Biol (2006) 0.97
The clinical significance of disseminated tumor cells in breast cancer. Nat Clin Pract Oncol (2007) 0.97
Transcriptome analysis reveals an osteoblast-like phenotype for human osteotropic breast cancer cells. Breast Cancer Res Treat (2006) 0.95
Src as a therapeutic target in anti-hormone/anti-growth factor-resistant breast cancer. Endocr Relat Cancer (2006) 0.93
Cancer dormancy: from mice to man. Cell Cycle (2006) 0.92
Bone metastasis: Osteoblasts affect growth and adhesion regulons in prostate tumor cells and provoke osteomimicry. Int J Cancer (2004) 0.91
Regulation of bone remodeling and emerging breakthrough drugs for osteoporosis and osteolytic bone metastases. Kidney Int Suppl (2003) 0.90
Roles of osteonectin in the migration of breast cancer cells into bone. J Cell Biochem (2006) 0.87
Inhibitors of the TGF-beta superfamily and their clinical applications. Mini Rev Med Chem (2006) 0.87
Matrix metalloproteinases and their inhibitors in bone: an overview of regulation and functions. Front Biosci (2006) 0.86
Multistate analysis of skeletal events in patients with bone metastases. Clin Cancer Res (2006) 0.86
Tumor dormancy: death and resurrection of cancer as seen through transgenic mouse models. Cell Cycle (2006) 0.84
Endothelin receptor antagonists: rationale, clinical development, and role in prostate cancer therapeutics. Curr Oncol Rep (2006) 0.80
New drugs: paliperidone, dasatinib, and decitabine. J Am Pharm Assoc (2003) (2007) 0.75
Osteochemonecrosis of jaws and bisphosphonates. Ir Med J (2007) 0.75
Insulin signaling in osteoblasts integrates bone remodeling and energy metabolism. Cell (2010) 5.08
Genetics, pathogenesis and complications of osteopetrosis. Bone (2007) 2.25
A six-gene signature predicting breast cancer lung metastasis. Cancer Res (2008) 2.09
Suppression of EGF-R signaling reduces the incidence of prostate cancer metastasis in nude mice. Endocr Relat Cancer (2006) 2.04
Osteoclast-poor human osteopetrosis due to mutations in the gene encoding RANKL. Nat Genet (2007) 2.04
Chloride channel ClCN7 mutations are responsible for severe recessive, dominant, and intermediate osteopetrosis. J Bone Miner Res (2003) 1.55
Impaired gastric acidification negatively affects calcium homeostasis and bone mass. Nat Med (2009) 1.52
Kinase-dependent and -independent roles of EphA2 in the regulation of prostate cancer invasion and metastasis. Am J Pathol (2009) 1.46
Impaired skeletal development in interleukin-6-transgenic mice: a model for the impact of chronic inflammation on the growing skeletal system. Arthritis Rheum (2006) 1.31
Involvement of PLEKHM1 in osteoclastic vesicular transport and osteopetrosis in incisors absent rats and humans. J Clin Invest (2007) 1.29
Inhibition of protein kinase c-Src reduces the incidence of breast cancer metastases and increases survival in mice: implications for therapy. J Pharmacol Exp Ther (2006) 1.26
Osteopenia, decreased bone formation and impaired osteoblast development in Sox4 heterozygous mice. J Cell Sci (2007) 1.20
Genotype-phenotype relationship in human ATP6i-dependent autosomal recessive osteopetrosis. Am J Pathol (2003) 1.09
Inhibition of protein kinase c-Src as a therapeutic approach for cancer and bone metastases. Anticancer Agents Med Chem (2008) 1.08
Bone cells and the mechanisms of bone remodelling. Front Biosci (Elite Ed) (2012) 1.06
A novel protein kinase C alpha-dependent signal to ERK1/2 activated by alphaVbeta3 integrin in osteoclasts and in Chinese hamster ovary (CHO) cells. J Cell Sci (2005) 1.06
Osteoclast receptors and signaling. Arch Biochem Biophys (2008) 1.05
Imbalance of osteoclastogenesis-regulating factors in patients with celiac disease. J Bone Miner Res (2004) 1.04
Osteomimicry: how tumor cells try to deceive the bone. Front Biosci (Schol Ed) (2010) 1.04
Modeled microgravity stimulates osteoclastogenesis and bone resorption by increasing osteoblast RANKL/OPG ratio. J Cell Biochem (2007) 1.01
The glycosaminoglycan-binding domain of PRELP acts as a cell type-specific NF-kappaB inhibitor that impairs osteoclastogenesis. J Cell Biol (2009) 0.99
Mechanisms inducing low bone density in Duchenne muscular dystrophy in mice and humans. J Bone Miner Res (2011) 0.97
Novel C16orf57 mutations in patients with Poikiloderma with Neutropenia: bioinformatic analysis of the protein and predicted effects of all reported mutations. Orphanet J Rare Dis (2012) 0.94
c-Src and IL-6 inhibit osteoblast differentiation and integrate IGFBP5 signalling. Nat Commun (2012) 0.94
Beta-Arrestin2 regulates RANKL and ephrins gene expression in response to bone remodeling in mice. J Bone Miner Res (2009) 0.92
Receptor activator of NF-kappaB ligand enhances breast cancer-induced osteolytic lesions through upregulation of extracellular matrix metalloproteinase inducer/CD147. Cancer Res (2010) 0.92
Characterization of the osteoblast-like cell phenotype under microgravity conditions in the NASA-approved Rotating Wall Vessel bioreactor (RWV). J Cell Biochem (2002) 0.91
In vivo bone metastases, osteoclastogenic ability, and phenotypic characterization of human breast cancer cells. Bone (2004) 0.91
Recent advances in mesenchymal stem cell immunomodulation: the role of microvesicles. Cell Transplant (2013) 0.89
A new heterozygous mutation (R714C) of the osteopetrosis gene, pleckstrin homolog domain containing family M (with run domain) member 1 (PLEKHM1), impairs vesicular acidification and increases TRACP secretion in osteoclasts. J Bone Miner Res (2008) 0.89
Global transcriptome analysis in mouse calvarial osteoblasts highlights sets of genes regulated by modeled microgravity and identifies a "mechanoresponsive osteoblast gene signature". J Cell Biochem (2009) 0.88
Increase in cytosolic Ca2+ induced by elevation of extracellular Ca2+ in skeletal myogenic cells. Am J Physiol Cell Physiol (2002) 0.87
Polymorphisms of the CLCN7 gene are associated with BMD in women. J Bone Miner Res (2005) 0.85
Evaluation of metastatic potential in prostate carcinoma: an in vivo model. Int J Oncol (2004) 0.85
NHERF1 acts as a molecular switch to program metastatic behavior and organotropism via its PDZ domains. Mol Biol Cell (2012) 0.84
Interaction of estrogen receptor alpha with protein kinase C alpha and c-Src in osteoblasts during differentiation. Bone (2004) 0.84
CLCN7 and TCIRG1 mutations differentially affect bone matrix mineralization in osteopetrotic individuals. J Bone Miner Res (2014) 0.83
Increased expression of a set of genes enriched in oxygen binding function discloses a predisposition of breast cancer bone metastases to generate metastasis spread in multiple organs. J Bone Miner Res (2012) 0.83
Expanding the role of Src and protein-tyrosine phosphatases balance in modulating osteoblast metabolism: lessons from mice. Biochimie (2010) 0.82
Tumor-stroma metabolic relationship based on lactate shuttle can sustain prostate cancer progression. BMC Cancer (2014) 0.82
Design of novel three-phase PCL/TZ-HA biomaterials for use in bone regeneration applications. J Mater Sci Mater Med (2010) 0.81
Characterization and expression of different pituitary adenylate cyclase-activating polypeptide/vasoactive intestinal polypeptide receptors in rat ovarian follicles. J Endocrinol (2006) 0.81
Osteoblast-conditioned media stimulate membrane vesicle shedding in prostate cancer cells. Int J Oncol (2006) 0.81
Lipocalin 2: a new mechanoresponding gene regulating bone homeostasis. J Bone Miner Res (2015) 0.80
Modulation of human estrogen receptor alpha F promoter by a protein kinase C/c-Src-dependent mechanism in osteoblast-like cells. J Mol Endocrinol (2006) 0.80
The tight relationship between osteoclasts and the immune system. Inflamm Allergy Drug Targets (2012) 0.80
Proline/arginine-rich end leucine-rich repeat protein N-terminus is a novel osteoclast antagonist that counteracts bone loss. J Bone Miner Res (2013) 0.80
Committed osteoclast precursors colonize the bone and improve the phenotype of a mouse model of autosomal recessive osteopetrosis. J Bone Miner Res (2010) 0.79
Osteopontin modulates prostate carcinoma invasive capacity through RGD-dependent upregulation of plasminogen activators. Biol Chem (2002) 0.78
Kinome profiling of osteoblasts on hydroxyapatite opens new avenues on biomaterial cell signaling. Biotechnol Bioeng (2014) 0.78
The C-terminal domain of chondroadherin: a new regulator of osteoclast motility counteracting bone loss. J Bone Miner Res (2014) 0.77
Bone remodeling: facts and perspectives. Arch Biochem Biophys (2008) 0.75
The central role of the skeleton in chronic diseases. Arch Biochem Biophys (2010) 0.75